The Use of a Multidrug Pill in Reducing Cardiovascular Events (UMPIRE) trial

Funding Activity

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Patients who have cardiovascular disease are at very high risk of experiencing a heart attack or stroke, and current guidelines recommend the long-term use of aspirin, blood pressure lowering drugs and a cholesterol lowering drug in such patients to reduce their risks. The proposed research will investigate whether the availability of a polypill (a single pill containing all these drugs) will help ensure patients are appropriately prescribed these treatments, and keep taking them long-term. Australian researchers will have a pivotal role in collecting and interpreting the data in this trial. In addition, Australian researchers will combine the findings of this study with results from similar trials being conducted in Australia (1600 patients, including 600 Aboriginal participants) and New Zealand (600 patients, including 600 Maori participants). This overview will provide very accurate information about the usefulness of the polypill, and how it should be used worldwide.

Funded Activity Details

Start Date: 01-01-2010

End Date: 01-01-2012

Funding Scheme: NHMRC Strategic Awards

Funding Amount: $314,535.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Preventive Medicine

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Blood pressure | Cardiovascular disease prevention | Clinical trials | Improving treatment compliance | Primary health care